This study found cardiac MRI gadolinium-based contrast agents are safe for patient use. Overall, there were only 556 acute adverse effects in 145,855 contrast-enhanced MRIs, with only 47 being classified as severe.
Feature | Magnetic Resonance Imaging (MRI)

October 29, 2020 — Contrast agents used to improve views of the heart on magnetic resonance imaging (MRI) carry a very ...

Home October 29, 2020
Home
News | Atrial Fibrillation

Oct. 29, 2020 — Boston Scientific initiated the CHAMPION-AF clinical trial to evaluate the safety and efficacy of the ...

Home October 29, 2020
Home
News | Ultrasound Imaging

October 28, 2020 — Northwestern Memorial Hospital is the first hospital in the United States to purchase Caption Health ...

Home October 28, 2020
Home
News

The September-October 2020 digital edition of Diagnostic and Interventional Cardiology (DAIC) magazine include links to ...

Home October 28, 2020
Home
Chest X-ray, posteroanterior view, of a 79-year-old man with history of a previous pacemaker, with abandoned right atrial and right ventricular pacing leads on the right side at time of new cardiac resynchronization therapy defibrillator implant on the left side. Arrows indicate a nodular opacity in the right midlung concerning for mass. Find more images of patients in this study in Radiology: Cardiothoracic Imaging.
Feature | Magnetic Resonance Imaging (MRI)

October 27, 2020 – Magnetic resonance imaging (MRI) examinations can be safely performed in patients with non-MR ...

Home October 27, 2020
Home
The Abiomed Breethe OXY-1 System has received U.S. FDA 510(k) clearance. 
Feature | ECMO Systems

October 26, 2020 — The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to Abiomed for an all-in-one ...

Home October 26, 2020
Home
News | Venous Therapies

October 26, 2020 — The U.S. Food and Drug Administration (FDA) has cleared the Medtronic Abre venous self-expanding ...

Home October 26, 2020
Home
News | Pulmonary Embolism

October 23, 2020 — Positive results were reported on the first 230 patients enrolled in its FLASH study, a real world ...

Home October 23, 2020
Home
News | FFR Technologies

October 23, 2020 – Results from the randomized controlled TARGET FFR trial show that while a physiology-guided ...

Home October 23, 2020
Home
News | FFR Technologies | Dave Fornell, Editor

October 22, 2020 – In the FORECAST randomized clinical trial, the use of fractional flow reserve (FFR) derived from ...

Home October 22, 2020
Home
Ori Ben-Yehuda, M.D., presenting the findings of the HOST-REDUCE-POLYTECH-ACS  study at TCT 2020 that showed durable polymer drug-eluting stents (DES) performed better than the bioresorbable polymer DES that were supposed to replace them with the promise of being safer and lowering overall cardiac event rates. #TCT2020 #TCTConnect
Feature | Stents | Dave Fornell, Editor

October 17, 2020 – In a surprise to many, a randomized clinical trial found that drug-eluting stents (DES) with durable ...

Home October 22, 2020
Home
News | Stents

October 22, 2020 – For patients undergoing percutaneous coronary intervention (PCI), treatment with the nanotechnology ...

Home October 22, 2020
Home
Videos | Hemodynamic Support Devices

Chuck Simonton, M.D., chief medical officer at Abiomed, discusses some of the new technologies and clinical trials the ...

Home October 20, 2020
Home
Videos | Coronavirus (COVID-19)

Chuck Simonton, M.D., chief medical officer at Abiomed, explains when advanced hemodynamic support is required in COVID ...

Home October 20, 2020
Home
Videos | Cath Lab

Dean Kereiakes, M.D., medical director, The Christ Hospital Heart and Vascular Center, medical director, The Christ ...

Home October 19, 2020
Home
Subscribe Now